WO2009129297A1 - Compositions pharmaceutiques orales semi-solides - Google Patents
Compositions pharmaceutiques orales semi-solides Download PDFInfo
- Publication number
- WO2009129297A1 WO2009129297A1 PCT/US2009/040644 US2009040644W WO2009129297A1 WO 2009129297 A1 WO2009129297 A1 WO 2009129297A1 US 2009040644 W US2009040644 W US 2009040644W WO 2009129297 A1 WO2009129297 A1 WO 2009129297A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- oral pharmaceutical
- alcohol
- posaconazole
- nonionic surfactant
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims abstract description 25
- 239000007787 solid Substances 0.000 title abstract description 12
- 229960001589 posaconazole Drugs 0.000 claims abstract description 70
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical group O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims abstract description 70
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 24
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 12
- 208000031888 Mycoses Diseases 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 31
- -1 polyoxyethylene Polymers 0.000 claims description 24
- 239000008247 solid mixture Substances 0.000 claims description 22
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 21
- 229920001400 block copolymer Polymers 0.000 claims description 15
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 14
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 14
- 229960004130 itraconazole Drugs 0.000 claims description 14
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 12
- 229960000580 terconazole Drugs 0.000 claims description 12
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 claims description 11
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 10
- 229960004884 fluconazole Drugs 0.000 claims description 10
- 229960004740 voriconazole Drugs 0.000 claims description 10
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 10
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 9
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 claims description 9
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 9
- 229940072106 hydroxystearate Drugs 0.000 claims description 9
- 229960004125 ketoconazole Drugs 0.000 claims description 9
- 229950004154 ravuconazole Drugs 0.000 claims description 9
- 229950005137 saperconazole Drugs 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- PCXMKBOWWVXEDT-UHFFFAOYSA-N difenamizole Chemical compound CN(C)C(C)C(=O)NC1=CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PCXMKBOWWVXEDT-UHFFFAOYSA-N 0.000 claims description 8
- 229950000061 difenamizole Drugs 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 8
- 229960003881 letrozole Drugs 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 claims description 7
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 7
- 229950003801 epirizole Drugs 0.000 claims description 7
- 238000013019 agitation Methods 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 229930003836 cresol Natural products 0.000 claims description 4
- 150000002191 fatty alcohols Chemical class 0.000 claims description 4
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 4
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 4
- 229960003511 macrogol Drugs 0.000 claims description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001987 poloxamine Polymers 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229940012831 stearyl alcohol Drugs 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- 241001480043 Arthrodermataceae Species 0.000 claims description 3
- 206010007134 Candida infections Diseases 0.000 claims description 3
- 201000003984 candidiasis Diseases 0.000 claims description 3
- 230000037304 dermatophytes Effects 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 229920001993 poloxamer 188 Polymers 0.000 description 14
- 230000036470 plasma concentration Effects 0.000 description 10
- 229940100692 oral suspension Drugs 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 7
- 239000006186 oral dosage form Substances 0.000 description 7
- 229940044519 poloxamer 188 Drugs 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 239000007909 solid dosage form Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 5
- 229960004217 benzyl alcohol Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 5
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 208000002474 Tinea Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 2
- 206010005913 Body tinea Diseases 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010008803 Chromoblastomycosis Diseases 0.000 description 2
- 208000015116 Chromomycosis Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000235402 Rhizomucor Species 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 206010043866 Tinea capitis Diseases 0.000 description 2
- 201000010618 Tinea cruris Diseases 0.000 description 2
- 206010043871 Tinea nigra Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009246 food effect Effects 0.000 description 2
- 235000021471 food effect Nutrition 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000009838 otomycosis Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000009642 tinea barbae Diseases 0.000 description 2
- 201000003875 tinea corporis Diseases 0.000 description 2
- 208000009189 tinea favosa Diseases 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010049591 Tinea imbricata Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001459572 Trichophyton interdigitale Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241000985906 Trichophyton soudanense Species 0.000 description 1
- 241000591119 Trichophyton sp. Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Definitions
- the present invention relates to novel oral pharmaceutical compositions comprising a semi-solid composition of a weakly basic and poorly-aqueous soluble azole, a monohydric organic alcohol and at least one nonionic surfactant.
- Such pharmaceutical compositions of posaconazole provide enhanced bioavailability of posaconazole in a solid dosage form as compared to an oral suspension.
- the invention also relates to methods for treating and/or preventing fiingal infections using said pharmaceutical compositions.
- weakly basic and poorly-aqueous soluble azole drugs examples include difenamizole, epirizole, fluconazole, itraconazole, ketoconazole, letrozole, posaconazole, ravuconazole, saperconazole, terconazole, and voriconazole.
- Certain of these weakly basic and poorly-aqueous soluble azole drugs, including, but not limited to, itraconazole, posaconazole and terconazole have been developed for treatment and/or prevention of fungal infections, including invasive fungal infections.
- Posaconazole is partially solubilized in an aqueous acidic solvent having a pH of about pH 1 or more acidic.
- a pH 1 aqueous solvent for example, posaconazole has a solubility of about 790 ⁇ g/mL.
- posaconazole in contrast, in a solvent less acidic than about pH > 4, posaconazole has a solubility of less than 1 ⁇ g/mL.
- U.S. Patent No. 5,834,472 ('472 Patent) describes a pharmaceutical composition of posaconazole, a non-ionic surfactant and a diluent.
- U.S. Patent No. 5,972,381 ('381 Patent) describes pharmaceutical compositions of posaconazole and a soluble or insoluble polymer, such as, povidone or crospovidone, the components being present in particularly recited ratios.
- U.S. Patent No. 5,846,971 ('971 Patent) describes pharmaceutical capsule compositions of posaconazole coated onto inert beads and a binder. None of the '472, '381, or the '971 Patents describe pharmaceutical compositions comprising posaconazole which provide consistent bioavailability.
- a solid dosage form of posaconazole which provides low variability in bioavailability and which reduces the "food effect", thus avoiding the need for administration in combination with food.
- a solid dosage form with sufficient bioavailability would provide a treatment regimen wherein the number of doses administered per day to achieve the desired therapeutic plasma concentration could be reduced.
- compositions with enhanced bioavailability of a weakly basic and poorly-aqueous soluble azole, including posaconazole would reduce the dose and/or absorption variability required for the same or better therapeutic effect, reduce the cost of goods for the product, and/or reduce the dosing regimen. Solid dosage forms of such drugs would provide greater convenience for patients and hence promote patient compliance.
- the present invention provides a pharmaceutical composition which can be incorporated into a solid dosage form suitable for oral administration.
- pharmaceutical compositions of the present invention meet the aforementioned need for reduced variability in the bioavailability of posaconazole, for example, a reduction of variability in bioavailability amongst a population of patients.
- pharmaceutical compositions of the present invention show a reduction in the food effect associated heretofore with oral administration of pharmaceutical formulations comprising posaconazole.
- pharmaceutical compositions of the invention are suitable for the preparation of dosage forms having ahigh drug loading, for example, a drug loading of > 100 mg drug per unit dosage form. Such pharmaceutical compositions may provide sufficient bioavailability to eliminate the need for administration with food and/or reduce the number of doses administered per day to achieve the desired therapeutic plasma concentration s) of posaconazole.
- the present invention provides an oral pharmaceutical composition
- an oral pharmaceutical composition comprising: a) posaconazole; b) a monohydric organic alcohol; and c) at least one nonionic surfactant; wherein the oral pharmaceutical composition is a semi-solid composition.
- the present invention provides an oral pharmaceutical composition
- an oral pharmaceutical composition comprising: a) a weakly basic and poorly-aqueous soluble azole which is difenamizole, epirizole, fluconazole, itraconazole, ketoconazole, letrozole, ravuconazole, saperconazole, terconazole, or voriconazole; b) a monohydric organic alcohol; and c) at least one nonionic surfactant; wherein the oral pharmaceutical composition is a semi-solid composition.
- the monohydric organic alcohol is isopropanol, t-butanol, phenol, cresol, or benzyl alcohol, or a mixture of two or more thereof. In some embodiments, the monohydric organic alcohol is benzyl alcohol.
- At least one nonionic surfactant is a polyoxyethylene fatty alcohol ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene fatty acid ester, a sorbitan ester, glycerol monostearate, a polyethylene glycol, a polypropylene glycol, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, an aryl alkyl polyether alcohol, a polyoxyethylene-polyoxypropylene copolymer, a poloxamine, polyvinyl alcohol, polyvinylpyrrolidone, or a macrogol.
- At least one nonionic surfactant is a polyethylene glycol 660 hydroxystearate, a polyethoxylated castor oil, or a block copolymer of ethylene oxide and propylene oxide.
- a pharmaceutical composition of the invention in some embodiments optionally it is preferred for a pharmaceutical composition of the invention to be combined with one or more pharmaceutically acceptable excipients.
- the preparatory method comprises the steps of: (a) dissolving posaconazole in a monohydric organic alcohol; and (b) adding at least one nonionic surfactant while applying vigorous agitation at a temperature from about 35 0 C to about 70 0 C.
- the present invention provides methods for preparing a a semi-solid composition pharmaceutical composition comprising a weakly basic and poorly-aqueous soluble azole comprising the steps of: (a) dissolving a weakly basic and poorly-aqueous soluble azole in a monohydric organic alcohol; and (b) adding at least one nonionic surfactant while applying vigorous agitation at a temperature from about 35 0 C to about 70 0 C.
- the azole employed it is preferred for the azole employed to be difenamizole, epirizole, fluconazole, itraconazole, ketoconazole, letrozole, ravuconazole, saperconazole, terconazole, or voriconazole.
- Another aspect of the invention provides methods for the treatment and/or prevention of a fungal infection comprising administering a pharmaceutical composition of the present invention, preferably a composition comprising posaconazole, to a patient in need thereof.
- a pharmaceutical composition of the present invention preferably a composition comprising posaconazole
- it is preferred to treat patients having a fungal infection is caused by a zygomycetes such as Mucor, Rhizopus, Rhizomucor etc.
- a dermatophyte such as Tinea corporis, Tinea cruris, Tinea pedis, Tinea barbae, Tinea capitis, Tinea nigra, Tinea favosa, or Tinea Imbricata or any other organism associated with onychomycosis.
- a pharmaceutical composition of the invention daily in a single or divided dose. In some embodiments administering a pharmaceutical composition of the invention in a daily divided dose, it is preferred to administer the composition of the invention twice-a-day.
- Figure 1 shows a linear: linear graph of the mean plasma concentration of posaconazole over a time period of 120 hrs post-dose following a single oral administration of 60 mg posaconazole to male cynomolgus monkeys in a semi-solid composition, or, as a comparative example, an oral suspension of posaconazole.
- Figure 2 is a graph of the mean Cmax concentration of posaconazole following a single oral administration of 60 mg posaconazole to male cynomolgus monkeys in a semisolid composition, or, as a comparative example, an oral suspension of posaconazole.
- Figure 3 is a graph of the mean exposure (AUC(tf)) of posaconazole following a single oral administration of 60 mg posaconazole to male cynomolgus monkeys in a semisolid composition, or, as a comparative example, an oral suspension of posaconazole.
- AUC is the area under the plasma concentration-time curve from time zero to a certain time period of the sample.
- AUC (4h) means the area under the plasma concentration-time curve from time zero to 4 hours.
- AUC(tf) is the area under the plasma concentration-time curve from time zero to the time of the final quantifiable sample.
- CL/F is the apparent total clearance of the drug from plasma after oral administration. CL/F is calculated by dividing the dose administered by the AUC.
- patient refers to an animal including a mammal (e.g., a human).
- pharmaceutically acceptable excipient refers to a non-toxic excipient that may be administered to a patient, together with the weakly basic and poorly-aqueous soluble azoles as described herein, which does not destroy the pharmacological activity thereof.
- treating or “treatment” is intended to mean mitigating or alleviating the symptoms of the recited condition, disease or disorder in a mammal such as a human.
- Pharmacokinetics refers to the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Pharmacokinetic parameters include, but are not limited to "maximum plasma concentration” or “Cmax,” “area under the plasma concentration time curve” or “AUC,” and “time to Cmax” or “Tmax.” As used herein, the term “tl/2" refers to the half-life of the drug.
- weakly basic and poorly-aqueous soluble azole refers to a compound comprising an azole functional group which is difenamizole, epirizole, fluconazole, itraconazole, ketoconazole, letrozole, posaconazole, ravuconazole, saperconazole, terconazole, or voriconazole. Especially preferred is posaconazole.
- the present invention provides oral semi-solid pharmaceutical compositions comprising posaconazole, a monohydric organic alcohol and at least one nonionic surfactant which meet the aforementioned need for sufficient and/or reduced variability in the bioavailability of posaconazole.
- Such pharmaceutical compositions include, but are not limited to, soft-gel capsules, hard shell gelatin capsules, and liquigel capsules.
- the pharmaceutical compositions provided herein are suitable for high drug loading dosage forms with > 100 mg drug per unit dosage form.
- the pharmaceutical compositions of the present invention provide sufficient bioavailability to eliminate the need for administration with food and/or reduce the number of doses administered per day to achieve the desired therapeutic plasma concentration(s) of posaconazole.
- the ranges (% w/w) of components for the semi-solid compositions provided herein are 5-30 % posaconazole, 5-45 % benzyl alcohol, 20-60% polyethylene glycol 660 hydroxystearate (e.g., Solutol® HS 15), 1-20 % a block copolymer of ethylene oxide and propylene oxide, represented by the formula
- the present invention also provides oral pharmaceutical compositions comprising a weakly basic and poorly-aqueous soluble azole which is difenamizole, epirizole, fluconazole, itraconazole, ketoconazole, letrozole, ravuconazole, saperconazole, terconazole, or voriconazole in a semi-solid composition.
- the weakly basic and poorly-aqueous soluble azole is the antifungal agent fluconazole, itraconazole, ketoconazole, ravuconazole, saperconazole, terconazole, or voriconazole.
- the weakly basic and poorly-aqueous soluble azole is the antifungal agent itraconazole or terconazole.
- Posaconazole has the following structure:
- Posaconazole available from Schering Corporation, Kenilworth, NJ., can be prepared according to Examples 24 and 32 of U.S. Pat. No. 5,661,151 and WO 95/17407. Posaconazole is partially solubilized in a strong acidic aqueous solution with a pH 1 or lower, where it has a solubility of about 790 ⁇ g/mL. In contrast, at pH > 4, posaconazole has a solubility of less than 1 ⁇ g/mL in aqueous solution.
- Terconazole available from Janssen Pharmaceutica, N.V., Beerse, Belgium and described in U.S. Patent No. 4,223,036, is practically insoluble ( ⁇ 0.1 mg/ml) in water has the following structure:
- TERCONAZOLE Fluconazole available from Pfizer, New York, N.Y. and described in U.S. Patent No. 6,790,957, is practically insoluble in water (about 1 ug/ml) and has the following structure:
- Voriconazole (formerly UK 109496), available from Pfizer, New York, N.Y. and described in U.S. Patent No. 5,278,175, has the following structure:
- Ketoconazole described in U.S. Patent No. 4,144,346, has the following structure:
- Epirazole (Omeprazole), described in U.S. Patent No. 4,255,431, has the following structure:
- Difenamizole described in JP 68 6621, which is practically insoluble in water has the following structure:
- the monohydric alcohol includes, but is not limited to, isopropanol, t-butanol, phenol, cresol, benzyl alcohol or a cycloalkyl alcohol, preferably benzyl alcohol.
- At least one nonionic surfactant is a polyoxyethylene fatty alcohol ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene fatty acid ester, a sorbitan ester, glycerol monostearate, a polyethylene glycol, a polypropylene glycol, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, an aryl alkyl polyether alcohol, a polyoxyethylene-polyoxypropylene copolymer, a poloxamine, polyvinyl alcohol, polyvinylpyrrolidone, or a macrogol.
- At least one nonionic surfactant is a polyethylene glycol 660 hydroxystearate, a polyethoxylated castor oil, or a block copolymer of ethylene oxide and propylene oxide.
- the semi-solid compositions of the present invention disclosed herein are formulated into pharmaceutical compositions for oral administration, herein termed "oral" pharmaceutical compositions.
- Suitable oral dosage forms include, but are not limited to, soft-gel capsules, hard shell gelatin capsules, and liquigel capsules.
- such oral compositions may optionally further comprise one or more pharmaceutically acceptable excipients.
- oral dosage forms as described herein have a drug loading capacity of at least 50 mg, 75 mg, 100 mg, or 125 mg per oral dosage form.
- excipients are well known in the art.
- excipients include, but are not limited to, surface active agents (e.g., sodium lauryl sulfate and polysorbate 80), drug complexing agents or solubilizers (e.g., polyethylene glycols, caffeine, xanthene, gentisic acid and cylodextrins), diluents (e.g., lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch), disintegrants (e.g., sodium starch glycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, low-substituted hydroxypropylcellulose (L-HPC (such as LH-21, and LH-Bl) and croscarmellose sodium), glidants (e.g., silicon dioxide and Talc), binders (e.g., methyl cellulose, microcrystalline cellulose, starch, HP
- the invention provides methods for preparing the semi-solid pharmaceutical compositions of the present invention.
- the invention provides methods for preparing a semi-solid composition of posaconazole, comprising: dissolving posaconazole in a monohydric organic alcohol and adding at least one nonionic surfactant while applying vigorous agitation at an elevated temperature.
- elevated temperatures may be from about 35 0 C to about 70 0 C.
- Suitable monohydric organic alcohols include isopropanol, t-butanol, phenol, cresol, and benzyl alcohol.
- the monohydric organic alcohol is benzyl alcohol.
- At least one nonionic surfactant is a polyoxyethylene fatty alcohol ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene fatty acid ester, a sorbitan ester, glycerol monostearate, a polyethylene glycol, a polypropylene glycol, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, an aryl alkyl polyether alcohol, a polyoxyethylene- polyoxypropylene copolymer, a poloxamine, polyvinyl alcohol, polyvinylpyrrolidone, or a macrogol.
- At least one nonionic surfactant is a polyethylene glycol 660 hydroxystearate, a polyethoxylated castor oil, or a block copolymer of ethylene oxide and propylene oxide.
- Cremophor EL® polyethoxylated castor oil
- Solutol® HSl 5 polyethylene glycol 660 hydroxystearate
- the composition is a semi-solid matrix.
- the resulting mixture is encapsulated in eiterh soft-gel capsules or in hard shell gelatin capsules.
- Example 1 Two exemplary semi-solid compositions of posaconazole referred to therein as “Exemplary Composition A” and “Exemplary Composition B,” are presented in Table 1.
- the ranges (% w/w) of components for the semi-solid compositions provided herein are 5-30 % posaconazole, 5- 45 % benzyl alcohol, 20-60% polyethoxylated castor oil (e.g., Cremophor EL®), 1-20 % Poloxamer 188 (e.g., Pluronic® F68).
- Table 1 Semi-solid compositions of posaconazole.
- the invention provides methods for preparing a semi-solid composition, comprising: a weakly basic and poorly-aqueous soluble azole which is difenamizole, epirizole, fluconazole, itraconazole, ketoconazole, letrozole, ravuconazole, saperconazole, terconazole, or voriconazole, a monohydric organic alcohol and at least one nonionic surfactant which comprises: dissolving the weakly basic and poorly-aqueous soluble azole in the monohydric organic alcohol followed by addition of a surfactant while applying vigorous agitation at an elevated temperature.
- Such elevated temperatures may be from about 35 0 C to about 70 0 C.
- the composition is a semi-solid matrix.
- the resulting mixture is encapsulated in either soft-gel capsules or in hard shell gelatin capsules.
- Another aspect of the invention provides methods for the treatment and/or prevention of a fungal infection in a patient comprising administering to the patient a composition according to the invention.
- the oral pharmaceutical compositions comprise posaconazole.
- Tinea corporis Tinea cruris, Tinea pedis, Tinea barbae, Tinea capitis, Tinea nigra, Tinea favosa,,or Tinea Imbricat ⁇
- Trichophyton sp. e.g., but not limited to, Trichophyton rubrum, Trichophyton interdigitale, Trichophyton tonsurans, Trichophyton soudanense, or Trichophyton violaceum
- Epidermophyton sp. e.g., but not limited to, Epidermophyton floccosum
- Microsporum sp e.g., but not limited to, Tinea corporis, Tinea cruris, Tinea pedis, Tinea barbae, Tinea capitis, Tinea nigra, Tinea favosa,,or Tinea Imbricat ⁇
- Trichophyton sp. e.g., but not limited
- NOXAFILTM posaconazole
- HSCT hematopoietic stem cell transplant
- GVHD graft-versus-host disease
- NOXAFILTM posaconazole
- oropharmygeal candidiasis including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.
- the pharmaceutical compositions described herein may be administered to a patient in need thereof every 8 hours, every 12 hours, or every 24 hours.
- a dose is administered to a patient in need thereof every 12 hours, or every 24 hours.
- a dose comprises at least one oral dosage form.
- a dose may comprise at least one additional oral dosage form administered simultaneously with the first dosage form, or within about 5 minutes, or even ten minutes of the first oral dosage form.
- compositions of the present invention are administered to a patient according to a dosing regimen.
- a dosing regimen for any particular patient will depend on a variety of factors, including species, age, body weight, body surface area, height, general health, sex, diet, time of administration, rate of excretion, drug combination, specific disease being treated, the severity of the condition, the renal and hepatic function of the patient, the particular active ingredient employed, and the judgment of the treating physician.
- composition B The two different posaconazole compositions examined were an oral suspension (described in U.S. Publication No. 2003/0055067) as well as a capsule dosage form of the semi-solid composition referred to herein as Exemplary Composition B.
- Table 3 Mean (CV, %) pharmacokinetic parameters for posaconazole compositions.
- Table 4 Individual and mean (CV, %) plasma concentration and pharmacokinetic parameters for posaconazole following a single oral administration of 60 mg posaconazole to male cynomolgus monkeys in oral suspension.
- Table 5 Individual and mean (CV, %) plasma concentration and pharmacokinetic parameters for posaconazole following a single oral administration of 60 mg posaconazole to male cynomolgus monkeys in Capsule (semi-solid posaconazole composition referred to herein as Exemplary Composition B).
- the semi-solid composition increased posaconazole exposure when compared to the oral suspension indicating an increase in enhanced bioavailability.
- the difference in mean AUC(tf) and mean Cmax was about 2 times for the semi-solid composition compared to the oral suspension.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques semi-solides qui comportent un azole soluble faiblement basique et faiblement aqueux, un alcool organique monohydrique et au moins un tensioactif non ionique. Dans le mode de réalisation idéal, l'azole soluble faiblement basique et faiblement aqueux est du posaconazole. La présente invention concerne également des procédés pour traiter et/ou empêcher des infections fongiques chez un mammifère à l’aide des compositions pharmaceutiques orales décrites ici.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4518308P | 2008-04-15 | 2008-04-15 | |
US61/045,183 | 2008-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009129297A1 true WO2009129297A1 (fr) | 2009-10-22 |
Family
ID=40756769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/040644 WO2009129297A1 (fr) | 2008-04-15 | 2009-04-15 | Compositions pharmaceutiques orales semi-solides |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009129297A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013186320A1 (fr) * | 2012-06-14 | 2013-12-19 | Sandoz Ag | Composition pharmaceutique comprenant du posaconazole cristallin |
US9040539B2 (en) | 2010-05-19 | 2015-05-26 | Sandoz Ag | Process for the preparation of chiral triazolones |
US9073904B2 (en) | 2010-05-19 | 2015-07-07 | Sandoz Ag | Preparation of posaconazole intermediates |
US9199919B2 (en) | 2010-05-19 | 2015-12-01 | Sandoz Ag | Process for the preparation of chiral hydrazides |
US9206146B2 (en) | 2010-05-19 | 2015-12-08 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
US9493428B2 (en) | 2011-06-16 | 2016-11-15 | Sandoz Ag | Process for the preparation of a chiral compound |
WO2023148763A1 (fr) * | 2022-02-01 | 2023-08-10 | Cipla Limited | Compositions pharmaceutiques injectables d'agents antifongiques de type azole |
WO2024127418A1 (fr) * | 2022-12-12 | 2024-06-20 | Cipla Limited | Compositions injectables de posaconazole |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
WO2003017986A1 (fr) * | 2001-08-27 | 2003-03-06 | Won Jin Biopharma Co., Ltd. | Compositions contenant de l'itraconazole et leurs procedes de preparation |
WO2005023262A1 (fr) * | 2003-09-09 | 2005-03-17 | Hanmi Pharm. Co., Ltd. | Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation |
WO2005074890A1 (fr) * | 2004-01-30 | 2005-08-18 | Pfizer Italia S.R.L. | Formulations pharmaceutiques a matrice semi-solide |
-
2009
- 2009-04-15 WO PCT/US2009/040644 patent/WO2009129297A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
WO2003017986A1 (fr) * | 2001-08-27 | 2003-03-06 | Won Jin Biopharma Co., Ltd. | Compositions contenant de l'itraconazole et leurs procedes de preparation |
WO2005023262A1 (fr) * | 2003-09-09 | 2005-03-17 | Hanmi Pharm. Co., Ltd. | Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation |
WO2005074890A1 (fr) * | 2004-01-30 | 2005-08-18 | Pfizer Italia S.R.L. | Formulations pharmaceutiques a matrice semi-solide |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9040539B2 (en) | 2010-05-19 | 2015-05-26 | Sandoz Ag | Process for the preparation of chiral triazolones |
US9073904B2 (en) | 2010-05-19 | 2015-07-07 | Sandoz Ag | Preparation of posaconazole intermediates |
US9199919B2 (en) | 2010-05-19 | 2015-12-01 | Sandoz Ag | Process for the preparation of chiral hydrazides |
US9206146B2 (en) | 2010-05-19 | 2015-12-08 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
US9493428B2 (en) | 2011-06-16 | 2016-11-15 | Sandoz Ag | Process for the preparation of a chiral compound |
WO2013186320A1 (fr) * | 2012-06-14 | 2013-12-19 | Sandoz Ag | Composition pharmaceutique comprenant du posaconazole cristallin |
WO2023148763A1 (fr) * | 2022-02-01 | 2023-08-10 | Cipla Limited | Compositions pharmaceutiques injectables d'agents antifongiques de type azole |
WO2024127418A1 (fr) * | 2022-12-12 | 2024-06-20 | Cipla Limited | Compositions injectables de posaconazole |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009129297A1 (fr) | Compositions pharmaceutiques orales semi-solides | |
US20240293406A1 (en) | Compositions and methods for treating myelofibrosis | |
US20110034478A1 (en) | Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs | |
US20060183766A1 (en) | Orally bioavailable CCI-779 formulations | |
US10543196B2 (en) | Oral dosage forms of bendamustine | |
AU2011260614B2 (en) | Oral dosage forms of bendamustine and therapeutic use thereof | |
AU2006295440A1 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
US20170165237A1 (en) | Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
AU2011260615B2 (en) | Oral dosage forms of bendamustine | |
US11285160B2 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
KR102081176B1 (ko) | 타크로리무스를 포함하는 서방형 약제학적 제제 | |
JP2023036663A (ja) | 重水素化ドンペリドンを含む製剤 | |
US20150141376A1 (en) | Pharmaceutical compositions of anti-viral compounds and process for preparation thereof | |
KR102301743B1 (ko) | 에피나코나졸 경구용 조성물 | |
RU2796537C2 (ru) | Составы, содержащие дейтерированный домперидон | |
WO2022123433A1 (fr) | Compositions pharmaceutiques orales de remdésivir | |
AU2013201986A1 (en) | Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients | |
WO2020049588A1 (fr) | Technologie pour améliorer la biodisponibilité d'un modulateur sélectif du récepteur des oestrogènes (serm) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09732348 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09732348 Country of ref document: EP Kind code of ref document: A1 |